Recent developments include capital raises through public offerings, ongoing clinical trial progress in Australia, reaffirmed regulatory engagement, and financial challenges highlighted in market analysis.

• Aethlon Medical priced a $4 million follow-on offering in July 2026 to support ongoing operations and clinical development [N1].
• The company reaffirmed regulatory engagement plans for the Hemopurifier, with stock price responding positively in May 2026 [N3].
• Q4 2026 earnings transcript released in June 2026 provided updates on clinical progress and financial condition [N2].
• Aethlon Medical cut losses in fiscal Q1 2025, indicating efforts to manage expenses [N8].
• The company completed a $4.5 million public offering of common stock and warrants in September 2025 to raise capital [N5][N6].
• Patents were secured for Hemopurifier use in Long COVID and coagulopathy-associated conditions in September 2025 [N7].
• Market analysis in February 2026 highlighted financial struggles, stockholder dilution, and market challenges facing the company [N4].

The Hemopurifier's unique mechanism targeting extracellular vesicles and enveloped viruses addresses significant unmet medical needs in oncology and infectious diseases. Positive clinical safety data and FDA Breakthrough Device designations support its potential utility. Ongoing clinical trials and preclinical research may expand its applications. The company's ability to secure regulatory approvals and establish manufacturing capabilities could enable commercialization in multiple indications.

The company is in early clinical development with limited patient data and no approved products. Regulatory approvals are pending and may face delays or challenges. Financial losses and the need for additional capital raise concerns about dilution and sustainability. The competitive landscape for immunotherapeutic devices and alternative treatments may limit market adoption. Clinical trial enrollment and execution risks exist, and some patents may expire before product approval.

Aethlon's moat is based on its proprietary lectin-affinity technology embodied in the Hemopurifier device, which uniquely targets extracellular vesicles and enveloped viruses implicated in cancer progression and viral diseases. The device has received FDA Breakthrough Device designation for two independent indications, supporting regulatory differentiation. The company holds a patent portfolio protecting its technology, though some patents may expire before regulatory approval. Clinical data and regulatory approvals are in early stages, and the device's novel mechanism and clinical applications provide potential competitive barriers.

• Clinical Development Risk: The Hemopurifier is in early-stage clinical trials with limited patient data; safety and efficacy outcomes remain uncertain.
• Regulatory Risk: Regulatory approvals are required before marketing; delays or denials could impact commercialization.
• Financial Risk: The company has reported net losses and relies on capital raises, which may dilute shareholders and affect financial stability.
• Market and Competitive Risk: Competition from other therapies and devices may limit adoption; market acceptance is uncertain.
• Patent and Intellectual Property Risk: Some patents may expire before regulatory approval, potentially reducing proprietary protection.

• Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device designed to remove enveloped viruses and extracellular vesicles (EVs) from biological fluids, addressing unmet needs in oncology, infectious diseases, and other conditions [S1].
• The Hemopurifier uses proprietary lectin-based technology to bind and remove EVs and enveloped viruses, which are implicated in immune suppression, metastasis, and disease progression [S1].
• The device has been evaluated in human studies involving 173 treatment sessions in 44 patients with viral infections or cancer, showing a safety profile consistent with extracorporeal therapy and removal of enveloped viruses [S1].
• The FDA has granted the Hemopurifier Breakthrough Device designation for two indications: treatment of advanced/metastatic cancer unresponsive to standard therapy, and treatment of life-threatening viruses without approved therapies [S1].
• Aethlon is conducting a safety, feasibility, and dose-finding clinical trial in Australia for patients with solid tumors resistant to anti-PD-1 monotherapy, with enrollment completed for two cohorts and no serious adverse events reported [S1].
• The company previously received regulatory approval for a similar oncology trial in India but chose not to proceed to conserve resources and focus on Australia [S1].
• The Hemopurifier has been used under emergency and investigational protocols to treat patients with Ebola, HIV, Hepatitis C, and COVID-19, demonstrating viral load reductions and safety in small studies [S1].
• The company maintains an open IDE for viral indications, including protocols for Ebola treatment in the US and Canada [S1].
• Preclinical studies have shown the Hemopurifier can remove platelet-derived EVs implicated in various diseases including cancer, lupus, multiple sclerosis, Alzheimer’s, sepsis, and COVID-19 [S1].
• Aethlon has published preclinical research on the Hemopurifier’s potential in Long COVID and coagulopathy associated conditions [S1].
• The company’s patent portfolio supports protection of the Hemopurifier technology, though some patents may expire before regulatory approval [S1].
• Financial snapshot as of June 30, 2026: cash and equivalents of $4.93 million, current assets of $5.61 million, current liabilities of $1.04 million, net loss of $1.55 million for the quarter, basic and diluted EPS of -$4.02, current ratio of 5.42, and cash ratio of 4.76 [S2].
• The company has conducted multiple public offerings to raise capital, including a $4 million follow-on offering in July 2026 and a $4.5 million public offering in September 2025 [N1][N5][N6].
• Recent news highlights include reaffirmation of regulatory engagement plans for the Hemopurifier and ongoing clinical development activities [N3][N2].
• The company faces financial challenges and risks related to stockholder dilution and market conditions as noted in recent analysis [N4].